76 completed, 34 unknown, 20 recruiting, 18 terminated. 169 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 169 | Completed 76, Unknown 34, Recruiting 20, Terminated 18, Not yet recruiting 10, Active not recruiting 4, Withdrawn 4, Suspended 3 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India Selpercatinib - Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 4 | Not yet recruiting | Eli Lilly and Company | 30 | 2026-10-01 | 2026-10-08 |
| Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy. Blood sampling, Tumor biopsies for biobank establishment (optional) - Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Head and Neck Squamous Cell Carcinoma | Phase 4 | Not yet recruiting | Centre Antoine Lacassagne | 110 | 2026-10-01 | 2026-09-15 |
| Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients. Experimental - Elderly, Breast Cancer | Phase 4 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 794 | 2026-09-01 | 2026-09-03 |
| A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy Shape-Sensing Robotic-Assisted Bronchoscopy with Cone-Beam CT (ssRAB with CBCT), CT-guided percutaneous lung nodule biopsy - Lung Cancer (Diagnosis), Lung Nodule | Phase 4 | Recruiting | Intuitive Surgical | 550 | 2026-08-28 | 2026-09-25 |
| CYTALUX Dose Extension Study CYTALUX (pafolacianine) injection - Cancer in the Lung, Ovarian Cancer | Phase 4 | Not yet recruiting | On Target Laboratories, LLC | 106 | 2026-08-15 | 2026-08-18 |
| Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) Paclitaxel Oral Solution, PD-1/PD-L1 inhibitor (eg. Tislelizumab) - Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 4 | Recruiting | Anhui Provincial Cancer Hospital | 107 | 2026-07-24 | 2026-08-04 |
| Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC Oral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT) - NSCLC (Non-small Cell Lung Cancer) | Phase 4 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 78 | 2026-06-25 | 2026-08-10 |
| Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. Osimertinib+cisplatin or carboplatin + pemetrexed Edit - Non-small Cell Lung Cancer | Phase 4 | Recruiting | AstraZeneca | 100 | 2026-05-26 | 2026-10-16 |
| A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer Tislelizumab and nintedanib - Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 4 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 20 | 2026-05-01 | 2026-03-20 |
| A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens Enhanced dermatologic management, Enhanced IRR Prophylaxis, Enhanced VTE Prophylaxis (Cohort 1 only) - NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism) | Phase 4 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 122 | 2026-04-30 | 2026-03-13 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive - NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer | Phase 4 | Recruiting | Rigel Pharmaceuticals | 12 | 2026-03-04 | 2026-08-10 |
| Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) Tislelizumab + platinum-based chemotherapy, Tislelizumab + platinum-based chemotherapy + focal radiotherapy - Non-Small Cell Lung Cancer | Phase 4 | Recruiting | Fujian Cancer Hospital | 60 | 2026-01-15 | 2026-01-06 |
| Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery in Video-Assisted Thoracoscopic Surgery Propofol, ciprofol - Myocardial Injury, Thoracic Diseases | Phase 4 | Recruiting | Tongji Hospital | 1058 | 2025-07-31 | 2026-01-28 |
| Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction Liposome Irinotecan, Platinum, Tislelizumab - Small Cell Lung Cancer | Phase 4 | Not yet recruiting | China Medical University, China | 31 | 2025-04-30 | 2025-04-30 |
| Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer Benmelstobart, Anlotinib, Carboplatin or cisplatin - Extensive-stage Small Cell Lung Cancer | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 50 | 2025-04-15 | 2025-04-23 |
| Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab Consolidation durvalumab - Non-small Cell Lung Cancer Stage III | Phase 4 | Recruiting | Idris Bahce | 38 | 2024-12-17 | 2026-08-20 |
| Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC Cryoablation - Non-Small-Cell Lung Cancer | Phase 4 | Not yet recruiting | Shanghai Chest Hospital | 20 | 2024-10-01 | 2024-08-30 |
| PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies Bio-bank repository, Quality of Life (QoL), G-Code - Non Small Cell Lung Cancer, Lung Cancer | Phase 4 | Recruiting | GFPC Investigation | 500 | 2024-09-26 | 2026-04-29 |
| EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing Endobronchial ultrasound with transbronchial needle aspiration, Bronchoscopy, Cryobiopsy - Lung Cancer | Phase 4 | Recruiting | Vanderbilt-Ingram Cancer Center | 250 | 2024-09-13 | 2026-02-02 |
Showing 20 of 169. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (91) · Lung Neoplasms (73) · Small Cell Lung Carcinoma (12) · Pleural Effusion, Malignant (9) · Melanoma (7) · Neoplasms (6) · Breast Neoplasms (5) · Head and Neck Neoplasms (5) · Ovarian Neoplasms (5) · Carcinoma (4) · Carcinoma, Renal Cell (4) · Kidney Neoplasms (4) · Lung Diseases (4) · Mesothelioma (4) · Pleural Effusion (4)
Neoplasms by Site (168) · Respiratory Tract Neoplasms (164) · Neoplasms (163) · Respiratory Tract Diseases (163) · Lung Diseases (153) · Carcinoma, Bronchogenic (99) · Bronchial Neoplasms (98) · Lung Neoplasms (85) · Neoplasms by Histologic Type (30) · Pathological Conditions, Signs and Symptoms (23) · Neoplasms, Glandular and Epithelial (18) · Pathologic Processes (16) · Urogenital Diseases (13) · Digestive System Diseases (12)
Carboplatin (13) · Pemetrexed (13) · Cisplatin (12) · Erlotinib Hydrochloride (11) · Paclitaxel (7) · Propofol (6) · icotinib (6) · Docetaxel (5) · Endostatins (5) · Gefitinib (5) · Nivolumab (5) · Saline Solution (5) · endostar protein (5) · tislelizumab (5) · Dexamethasone (4)
AstraZeneca (9) · Hoffmann-La Roche (6) · Betta Pharmaceuticals Co., Ltd. (4) · Novartis Pharmaceuticals (4) · Radboud University Medical Center (4) · Boehringer Ingelheim (3) · China Medical University, China (3) · Eli Lilly and Company (3) · Pfizer (3) · Simcere Pharmaceutical Co., Ltd (3) · Amgen (2) · Bristol-Myers Squibb (2) · CSA Medical, Inc. (2) · Duke University (2) · Guangdong Association of Clinical Trials (2)
China (50) · United States (30) · Netherlands (14) · France (12) · Taiwan (11) · India (10) · Spain (8) · Brazil (7) · Germany (7) · South Korea (7) · Switzerland (7) · Denmark (6) · Italy (6) · Poland (6) · Russia (6)
Rob ter Heine, PhD (3) · Daniel Franzen, MD (2) · Yuh-Min Chen, MD, PhD. (2) · A.J. van der Wekken, PhD (1) · Abdulrahman Jazieh, MD/MPH (1) · Adrienne H Brouwers, MD PhD (1) · Ahmed F Koraitim, MD (1) · Andre GS Leite, PhD (1)
PMID 35048355, PMID 36053283, PMID 10735670, PMID 11506101, PMID 16211735, PMID 18165618, PMID 19349389, PMID 19484483, PMID 19664781, PMID 20118030, PMID 21266057, PMID 21439671, PMID 21775497, PMID 22241828, PMID 2245677, PMID 22512843, PMID 22681919, PMID 23053582, PMID 23182663, PMID 23475281, PMID 23733379, PMID 24255769, PMID 24778393, PMID 25359988, PMID 25546556, PMID 25855621, PMID 26028407, PMID 26291008, PMID 27117455, PMID 27413711, PMID 27566586, PMID 27614989, PMID 28196905, PMID 28535181, PMID 29203498, PMID 29270080, PMID 29958220, PMID 30013197, PMID 30082870, PMID 30280641, PMID 31200823, PMID 31299247, PMID 31590988, PMID 31641390, PMID 32599071, PMID 33096027, PMID 33300144, PMID 33333328, PMID 33538338, PMID 33737339
2023 (3), 2016 (2), 2017 (2), 2019 (2), 2004 (1), 2014 (1), 2018 (1), 2025 (1), R01CA091912 (1), U01CA063673 (1)